Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Macrophages within the tumor microenvironment promote angiogenesis, extracellular matrix breakdown, and tumor cell migration, invasion, and metastasis. Activation of the urokinase plasminogen activator (uPA) and its receptor (uPAR) axis promotes prostate cancer tumorigenicity, invasion, metastasis, and survival within the tumor microenvironment. The link between macrophage infiltration and the uPA/uPAR axis in prostate cancer development has not been established, although it has been reported that uPA plays a critical role inmonocyte and macrophage chemotaxis. In this study, murine prostate cancer RM-1 cells were subcutaneously inoculated into wild-type (WT), uPA(-/-), and uPAR(-/-) mice. Tumor volume was significantly diminished in both uPA(-/-) and uPAR(-/-) mice compared with WT controls. Greater inhibition of tumor volume was also observed in uPA(-/-) mice compared with uPAR(-/-) mice, suggesting the important contribution of stromal-derived uPA to sustain the tumor growth. Immunohistochemical staining revealed that tumors in uPA(-/-) and uPAR(-/-) mice displayed significantly lower proliferative indices, higher apoptotic indices, and less neovascularity compared with the tumors in WT mice. Tumors in uPA(-/-) and uPAR(-/-) mice displayed significantly less macrophage infiltration as demonstrated by F4/80 staining and MAC3(+) cell numbers by flow cytometry compared with the tumors from WT mice. These findings suggest that the uPA/uPAR axis acts in both autocrine and paracrine manners in the tumor microenvironment, and activation of uPA/uPAR axis is essential for macrophage infiltration into prostate tumors.
Department of Internal Medicine and Urology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109-5946, USA. jzhangqi@umich.edu
Jian
J
Zhang
Sudha
S
Sud
Kosuke
K
Mizutani
Margaret R
MR
Gyetko
Kenneth J
KJ
Pienta
D000818:Animals; D017209:Apoptosis / Q000235:genetics; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation; D017077:Culture Media, Conditioned; D066298:In Vitro Techniques; D008264:Macrophages / Q000473:pathology* / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009154:Mutation; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D055293:Receptors, Urokinase Plasminogen Activator / Q000235:genetics / Q000378:metabolism*; D047368:Tumor Burden; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics / Q000378:metabolism*
D017077:Culture Media, Conditioned; C524899:Plaur protein, mouse; D055293:Receptors, Urokinase Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
Eur J Cancer. 2001 May;37(8):1033-40
11334730
Int J Oncol. 1999 Mar;14(3):535-41
10024688
Nature. 1994 Mar 31;368(6470):419-24
8133887
Int J Cancer. 2005 Mar 1;113(6):870-80
15515049
Hum Pathol. 2006 Nov;37(11):1442-51
16949925
Histochem Cell Biol. 2004 Apr;121(4):299-310
15042374
J Biol Chem. 2005 Oct 28;280(43):36529-40
16127174
Nature. 2002 Dec 19-26;420(6917):860-7
12490959
J Steroid Biochem Mol Biol. 1995 May;52(5):403-13
7538321
J Clin Oncol. 2007 Feb 1;25(4):349-55
17264329
Eur J Immunol. 1981 Oct;11(10):805-15
7308288
J Clin Invest. 1996 Apr 15;97(8):1818-26
8621764
Eur J Cancer. 2006 Apr;42(6):717-27
16520032
J Clin Oncol. 2007 Feb 1;25(4):347-8
17264328
Neoplasia. 2008 May;10(5):439-49
18472961
Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36
20027185
Clin Cancer Res. 2009 Jan 15;15(2):452-9
19147749
J Clin Invest. 1994 Apr;93(4):1380-7
8163642
Cancer Res. 2007 Feb 1;67(3):930-9
17283123
Cell. 1989 Mar 24;56(6):917-30
2538247
J Leukoc Biol. 2009 Nov;86(5):1065-73
19741157
J Clin Invest. 1996 Jun 1;97(11):2680-4
8647963
Thromb Res. 1988 May 15;50(4):527-35
3137679
Future Oncol. 2009 Nov;5(9):1487-99
19903074
J Clin Invest. 1996 Feb 1;97(3):870-8
8609247
Int J Cancer. 1992 Apr 1;50(6):871-3
1555885
Lancet. 2001 Feb 17;357(9255):539-45
11229684
Prostate. 1999 May;39(2):123-9
10221568
Blood Coagul Fibrinolysis. 1990 Dec;1(6):681-7
2133247
J Lab Clin Med. 1988 Jan;111(1):42-51
3121772
Cancer Treat Rev. 2007 Oct;33(6):521-7
17658220
Cancer Res. 2000 Oct 15;60(20):5839-47
11059781
J Immunol. 2008 Jan 15;180(2):1179-88
18178858
Prostate. 2009 Nov 1;69(15):1613-23
19585491
Mol Cancer Ther. 2008 Oct;7(10):3203-11
18852124
Am J Med Sci. 1996 Jul;312(1):8-11
8686732
J Cell Biochem. 2010 Mar 1;109(4):726-36
20052673